Akero Q1 2022 Earnings Report
Key Takeaways
Akero Therapeutics reported first quarter financial results with cash, cash equivalents, and short-term marketable securities totaling $165.4 million. The company's operating expenses were $26.1 million, resulting in a net loss of $26.0 million, or $0.74 per share.
Cash, cash equivalents and short-term marketable securities were $165.4 million.
Cash is expected to fund operations into the third quarter of 2023.
Research and development expenses were $20.5 million, an increase from $10.6 million in the comparable period of 2021.
Total operating expenses were $26.1 million, compared to $15.1 million for the comparable period in 2021.
Akero
Akero
Forward Guidance
Akero believes that its cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan into the third quarter of 2023.